BNGO · Bionano Genomics, Inc. · Executive Compensation
$1.00
-0.04 (-3.85%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Nov 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, we determined that there is substantial doubt about our ability to continue as a going concern within 12 months after the date that the financial statements included in this Quarterly Report are issued.”View the 10-Q filed Nov 10, 2026
Market Cap
$13.99M
Shares
13.99M
Volume · Nov 13
557.57K
Avg daily vol (3M)
965.62K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| R. Erik Holmlin | Chief Executive Officer | $1,112,742 |
| Alka Chaubey | Ph.D., FACMG Chief Medical Officer | $756,329 |
| Mark Oldakowski | Chief Operating Officer | $756,329 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| R. Erik Holmlin | Chief Executive Officer | $989,677 |
| Mark Oldakowski | Chief Operating Officer | $663,369 |
| Alka Chaubey | Ph.D., FACMG Chief Medical Officer | $661,908 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| R. Erik Holmlin | Chief Executive Officer | $1,254,659 |
| Mark Oldakowski | Chief Operating Officer | $884,780 |
| Alka Chaubey | Ph.D., FACMG Chief Medical Officer | $864,780 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Soheil Shams | Former Chief Informatics Officer | $11,344,793 |
| R. Erik Holmlin | Chief Executive Officer | $2,766,572 |
| Mark Oldakowski | Chief Operating Officer | $1,500,824 |
| Alka Chaubey | Ph.D., FACMG Chief Medical Officer | $1,317,829 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| R. Erik Holmlin | Chief Executive Officer | $7,580,471 |
| Mark Oldakowski | Chief Operating Officer | $3,105,160 |
| Richard Shippy | Chief Business Officer Represent the aggregate grant date fair value of time-based restricted stock unit, or RSU, awards and performance-vesting restricted stock unit, or PSU, awards for the applicable fiscal year calculated in accordance with FASB ASC 718, Compensation – Stock Compensation. The grant date fair value of each RSU award is measured based on the closing price of our common stock on the date of grant. Included is a PSU award granted to Dr. Holmlin that, in order to vest, requires achievement of certain performance-based vesting conditions during a four-year performance period. The grant date fair value of this PSU award was determined in accordance with FASB ASC 718 based upon the then-probable outcome of the performance-based vesting conditions underlying such award. The maximum potential value of this PSU award, assuming the highest level of performance achievement, calculated in accordance with FASB ASC 718, was $1,374,600. These amounts do not reflect whether the NEO has actually realized or will realize a financial benefit from the awards upon the vesting of the granted stock awards, or the sale of the shares underlying such stock awards. For additional detail, see Note 10 of the Annual Report. | $2,211,220 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| R. Erik Holmlin | Chief Executive Officer | $707,573 |
| Mark Oldakowski | Chief Operating Officer | $454,098 |
| Christopher Stewart | Chief Financial Officer | $252,378 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| R. Erik Holmlin | Chief Executive Officer | $898,590 |
| Mark Oldakowski | Chief Operating Officer | $546,854 |
| Warren Robinson | Chief Commercial Officer | $534,794 |
| Mike Ward | Former Chief Financial Officer | $446,676 |
| Christopher Stewart | Chief Financial Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| R. Erik Holmlin | Chief Executive Officer | $2,527,257 |
| Warren Robinson | Chief Commercial Officer | $897,408 |
| Mike Ward | Former Chief Financial Officer | $841,676 |
| Mark Oldakowski | Chief Operating Officer | $612,424 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Alka Chaubey, Ph.D. | Chief Medical Officer | Resigned | 2026-06-05 |
| Christopher J. Twomey | Lead Independent Director | Appointed | 2026-05-06 |
| Albert A. Luderer, Ph.D. | Interim Chief Executive Officer | Appointed | 2026-05-06 |
| R. Erik Holmlin, Ph.D. | Board of Directors | Resigned | 2026-05-06 |
| Kristiina Vuori, M.D., Ph.D. | member of the Audit Committee of the Board | Appointed | 2025-06-13 |
| Mark Adamchak | principal accounting officer | Appointed | 2024-09-09 |
| R. Erik Holmlin | principal financial officer | Appointed | 2024-09-09 |
| Gülsen Kama | Chief Financial Officer | Terminated | 2024-09-09 |
| Christopher Stewart | Chief Financial Officer | Resigned | 2023-08-14 |
| Gülsen Kama | Chief Financial Officer | Appointed | 2023-08-14 |
| Richard Shippy | Chief Business Officer | Resigned | 2022-11-18 |
Leadership
- Albert A. Luderer, Ph.D. CEO, CFO
- R. Erik Holmlin CEO, Board Member
- Albert Luderer Chairman
- Gülsen Kama CFO
- Mike Ward CFO
- Mark Oldakowski COO
- Jonathan Dixon General Counsel
- Mark Adamchak Chief Accounting Officer
- Aleksandar Rajkovic Board Member
- Aleksandar Rajkovic, M.D., Ph.D. Board Member
- Christopher J. Twomey Board Member
- Christopher Twomey Board Member
- David L. Barker Board Member
- Kristiina Vuori Board Member
- Kristiina Vuori, M.D., Ph.D. Board Member
- Yvonne Linney Board Member
Key facts
CIK
1411690
CUSIP
09075F404
13F (30d)
44 filings
26 filers
Visit website
Investor relations